Risk Reduction in Coronary Heart Disease (SPREK!)

Sorlandet Hospital HF

Status: Completed

Conditions: Coronary Heart Disease

Treatments: Drug: betablocker, diuretics, ACEI, ARB,; Behavioral: training; Behavioral: weight reduction; Drug: metformin, glimepiride, insulin; Drug: statins, ezetimibe; Behavioral: smoking cessation; Biological: influenza vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT00679237

S-07041a (REK)

Details and patient eligibility

About

Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death

Enrollment: 1,600 patients

Sex: All

Ages: 18 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• acute myocardial infarction, CABG or PCI

Exclusion criteria

• Age < 18 and age > 80
• pregnant
• critical illness
• drug abuse

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,600 participants in 2 patient groups

Multifactorial intervention

Active Comparator group

Description:

Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin

Treatment:

Biological: influenza vaccine

Behavioral: training

Drug: metformin, glimepiride, insulin

Drug: statins, ezetimibe

Drug: betablocker, diuretics, ACEI, ARB,

Behavioral: weight reduction

Behavioral: smoking cessation

Control

No Intervention group

Description:

no intervention